Focus on Optimized Dosing of Ibrutinib Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Varsha Gandhi, PhD, on Ibrutinib

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Amit Sanyal, MD: A Clinician’s Perspective

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Apr

Today In Oncology

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Amit Sanyal, MD: A Clinician’s Perspective

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Long-Term Immunotherapy for Alveolar Soft Part Sarcoma

AMA Data Show Nearly 50 Percent of Surveyed Oncologists Reported Burnout in 2025

Unique Phase I NSCLC Trial Sites Decreasing in United States

Overall Survival With Addition of Relacorilant to Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer

Tislelizumab With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer